Method for alleviating asthenopia and liquid composition for ophthalmic use

Abstract

The present invention relates to a method for alleviating asthenopia and a liquid composition for ophthalmic use. Specifically, on one hand, the invention relates to a liquid composition for eyes. The invention relates to a skin-care lotion, which is prepared from the following components: glycerol, p-hydroxyacetophenone, sodium hyaluronate, propylene glycol, menthol, borneol, methyl diisopropyl propionamide, menthol, SOLUBILISANT LRI, edetate disodium, water-locking magnetite, radix gentianae extract, totarol, sodium citrate, ectodoine, ergothioneine, hydrolyzed red algae extract and water. Furthermore, the invention also relates to an application of the liquid composition in preparation of a product for relieving eye asthenopia for eye use. The liquid composition of the present invention exhibits excellent properties, for example as described in the specification.

Description

Technical Field

[0001] The present invention belongs to the field of medical technology, relates to a method for relieving eye fatigue, and also relates to a liquid composition for use in the eye prepared for the method for relieving eye fatigue. The liquid composition for use in the eye of the present invention exhibits excellent performance. Background Art

[0002] The eye is the human visual organ, which consists of the eyeball and its auxiliary structures. The eyeball is the main part of the visual organ, which has two functions: refraction imaging and photosensitivity transduction. The auxiliary parts of the eye include the eyelid, conjunctiva, lacrimal apparatus, eye muscles, and orbital fascia and fat, which protect, move and support the eyeball. The perfection of the structures of the eye is of great significance to the completion of the visual function of the eye.

[0003] The normal function of the eyes plays an important role in people's high-quality life. However, with the popularization of electronic products, people spend more and more time on electronic screens such as mobile phones and computers, especially today when mobile networks are well developed. For example, according to statistics, the number of Internet users in China has exceeded 1 billion, with 1.08 billion mobile phone users, 897 million computer users, nearly 223 million Internet users are students, and the average daily online time of Internet users is 4.9 hours. In the information age, people's eye use time has increased several times compared with the past few decades, and they rely more and more on video display terminals such as computers and televisions for various activities. In recent years, the number of people suffering from visual fatigue in my country has increased exponentially. According to relevant statistics, there are now as many as 150 million people. However, people's vision care concepts have not kept up. Visual fatigue is a common disease in ophthalmology, a syndrome of visual fatigue caused by various reasons. Its clinical manifestations are varied, and transient visual function impairment or a series of eye discomfort often occurs when the eyes are used at close range for a long time or shortly after using the eyes. In mild cases, symptoms include swelling, dryness, photophobia, burning, redness, dull pain around the eye sockets, or swelling and pain at the root of the nose and forehead, and blurred vision. In severe cases, symptoms include swelling and pain in the eyeballs, severe headaches or migraines, cold sweats, pale complexion, slow heartbeats, or a tightness in the precordial area. Some may also show symptoms such as inability to concentrate on work, mental depression, fear of reading, insomnia, and memory loss. If not treated in time, it will cause vision loss and eventually lead to myopia, excessive psychological tension, three-dimensional concentration, and neurasthenia. There are four main reasons for the formation: excessive use of the eyes, improper use of the eyes, disease, and accommodative visual fatigue. After visual fatigue occurs frequently, continuing to use electronic screens for a long time will cause the eyes to have lower and lower tolerance and become more and more prone to dryness.

[0004] A common consequence of using your eyes for a long time on electronic screens is dry eye syndrome. Today, the number of people suffering from dry eye syndrome in my country is as high as 360 million, especially white-collar workers, who are the hardest hit. 80% of white-collar workers suffer from eye fatigue. These alarming figures will cause a huge burden on ophthalmic medical care. It is of great significance to prevent and intervene before the eye disease develops to the point where it deeply affects life.

[0005] The existing method of relieving eye fatigue is mainly to put eye drops into the eyes. Although this method is effective, it will increase the burden on the eyeball, and since conventional eye drops are added with preservatives, this may cause additional damage to the eyeball.

[0006] However, solving eye fatigue by applying drugs externally without entering the eyes has very positive technical significance, especially since the drugs will not touch the internal eye structure and thus can avoid adverse side effects. Summary of the invention

[0007] The object of the present invention is to provide a method for relieving eye fatigue, in particular to provide a method for relieving eye fatigue by using eye protection liquid outside and around the eye. Another object of the present invention is to provide a liquid composition for the eye in the above-mentioned method for relieving eye fatigue, which can be called eye protection liquid or eye protection essence.

[0008] To this end, the first aspect of the present invention provides a liquid composition for eye use, which comprises the following components in weight proportions: Glycerin 5.4g~6.6g, p-Hydroxyacetophenone 0.27g ~0.33g, Sodium hyaluronate 0.045g~0.055g, Propylene glycol 5.4g ~6.6g, Menthyl glycol 0.018g~0.022g, Borneol 0.018g ~0.022g, Methyl diisopropyl propionamide 0.27g~0.33g, Menthol 0.018g ~0.022g, SOLUBILISANT LRI is 0.225g ~ 0.275g, Edetate disodium 0.027g~0.033g, Water-locking magnet 0.45g ~0.55g, Gentiana root extract 0.18g~0.22g, Totarol 0.045g ~0.055g, Sodium citrate 0.0106g~0.013g, Ecdoin 0.009g ~0.011g, Ergothioneine 0.0045g~0.0055g, Hydrolyzed red algae extract 0.0045g ~0.0055g, Add appropriate amount of water to 100g.

[0009] The liquid composition for ocular use according to the first aspect of the present invention is prepared by a method comprising the following steps: 1) Heat half of the prescribed amount of glycerol and p-hydroxyacetophenone in a water bath to completely dissolve them as pre-liquid A for later use; 2) Pre-dispersing sodium hyaluronate, 10 times its weight of water, and the remainder of glycerol to prepare pre-liquid B for later use; 3) Propylene glycol, menthyl glycol and borneol are stirred evenly, heated to 60°C-70°C to dissolve the materials, then cooled to room temperature, methyl diisopropyl propionamide and menthol are added, stirred to dissolve, and then SOLUBILISANT LRI is added and stirred evenly to prepare preformed liquid C; 4) Place an appropriate amount (e.g., about 60% of the prescribed amount) of water and disodium edetate in a liquid preparation pot, stir to dissolve, add preformed liquid B while stirring, then heat to 85°C while stirring, continue to keep warm and stir for 30 minutes, cool to 40°C, add preformed liquid A while stirring, and stir evenly; 5) Add prefabricated liquid C, water-locking magnet, gentian root extract, totarol, sodium citrate, ectoine, ergothioneine, hydrolyzed red algae extract, and the remainder of water to the liquid obtained in the previous step in sequence, stir to dissolve at a temperature of 40°C-45°C, filter with 0.8µm and 0.45µm microporous filter membranes in sequence, and pack to obtain; for example, the liquid composition also includes threonine and / or sodium bisulfite; for example, it also includes 0.18g~0.22g of threonine and / or 0.0675g~0.0825g of sodium bisulfite; for example, the threonine and / or sodium bisulfite are added together with ectoine.

[0010] The liquid composition for ocular use according to the first aspect of the present invention comprises the following components in weight proportions: Glycerin 6g, p-Hydroxyacetophenone 0.3g, Sodium hyaluronate 0.05g, Propylene glycol 6g, Menthyl glycol 0.02g, Borneol 0.02g, Methyl diisopropyl propionamide 0.3g, Menthol 0.02g, SOLUBILISANT LRI is 0.25g, Edetate disodium 0.03g, 0.5g water-locking magnet Gentiana root extract 0.2g, Totarol 0.05g, Sodium citrate 0.0118g, Ecdoin 0.01g, Threonine 0.2g, Sodium bisulfite 0.075g, Ergothioneine 0.005g, Hydrolyzed red algae extract 0.005g, Add appropriate amount of water to 100g.

[0011] The liquid composition for ocular use according to the first aspect of the present invention comprises the following components in weight proportions: Glycerin 5.4g, p-Hydroxyacetophenone 0.33g, Sodium hyaluronate 0.045g, Propylene glycol 6.6g, Menthyl glycol 0.018 g, Borneol 0.022g, Methyl diisopropyl propionamide 0.27 g, Menthol 0.022g, SOLUBILISANT LRI is 0.275g, Disodium edetate 0.027g, Water-locking magnet 0.55g, Gentiana root extract 0.18g, Totarol 0.055g, Sodium citrate 0.0106g, Ecdoin 0.011g, Threonine 0.18g, Sodium bisulfite 0.0825 g, Ergothioneine 0.0045g, Hydrolyzed red algae extract 0.0055g, Add appropriate amount of water to 100g.

[0012] The liquid composition for ocular use according to the first aspect of the present invention comprises the following components in weight proportions: Glycerin 6.6g, p-Hydroxyacetophenone 0.27g, Sodium hyaluronate 0.055g, Propylene glycol 5.4g, Menthyl glycol 0.022 g, Borneol 0.018g, Methyl diisopropyl propionamide 0.33 g, Menthol 0.018g, SOLUBILISANT LRI is 0.225g, Disodium edetate 0.033g, Water-locking magnet 0.45g, Gentiana root extract 0.22g, Totarol 0.045g, Sodium citrate 0.013g, Ecdoin 0.009g, Threonine 0.22g, Sodium bisulfite 0.0675g, Ergothioneine 0.0055g, Hydrolyzed red algae extract 0.0045g, Add appropriate amount of water to 100g.

[0013] Furthermore, the second aspect of the present invention provides the use of a liquid composition in preparing a product for relieving eye fatigue, wherein the liquid composition comprises the following components in weight proportion: Glycerin 5.4g~6.6g, p-Hydroxyacetophenone 0.27g ~0.33g, Sodium hyaluronate 0.045g~0.055g, Propylene glycol 5.4g ~6.6g, Menthyl glycol 0.018g~0.022g, Borneol 0.018g ~0.022g, Methyl diisopropyl propionamide 0.27g~0.33g, Menthol 0.018g ~0.022g, SOLUBILISANT LRI is 0.225g ~ 0.275g, Edetate disodium 0.027g~0.033g, Water-locking magnet 0.45g ~0.55g, Gentiana root extract 0.18g~0.22g, Totarol 0.045g ~0.055g, Sodium citrate 0.0106g~0.013g, Ecdoin 0.009g ~0.011g, Ergothioneine 0.0045g~0.0055g, Hydrolyzed red algae extract 0.0045g ~0.0055g, Add appropriate amount of water to 100g.

[0014] According to the use of the second aspect of the present invention, the liquid composition is prepared by a method comprising the following steps: 1) Heat half of the prescribed amount of glycerol and p-hydroxyacetophenone in a water bath to completely dissolve them as pre-liquid A for later use; 2) Pre-dispersing sodium hyaluronate, 10 times its weight of water, and the remainder of glycerol to prepare pre-liquid B for later use; 3) Propylene glycol, menthyl glycol and borneol are stirred evenly, heated to 60°C-70°C to dissolve the materials, then cooled to room temperature, methyl diisopropyl propionamide and menthol are added, stirred to dissolve, and then SOLUBILISANT LRI is added and stirred evenly to prepare preformed liquid C; 4) Place an appropriate amount (e.g., about 60% of the prescribed amount) of water and disodium edetate in a liquid preparation pot, stir to dissolve, add preformed liquid B while stirring, then heat to 85°C while stirring, continue to keep warm and stir for 30 minutes, cool to 40°C, add preformed liquid A while stirring, and stir evenly; 5) Add prefabricated liquid C, water-locking magnet, gentian root extract, totarol, sodium citrate, ectoine, ergothioneine, hydrolyzed red algae extract, and the remainder of water to the liquid obtained in the previous step in sequence, stir to dissolve at a temperature of 40°C-45°C, filter with 0.8µm and 0.45µm microporous filter membranes in sequence, and pack to obtain; for example, the liquid composition also includes threonine and / or sodium bisulfite; for example, it also includes 0.18g~0.22g of threonine and / or 0.0675g~0.0825g of sodium bisulfite; for example, the threonine and / or sodium bisulfite are added together with ectoine.

[0015] According to the use of the second aspect of the present invention, the liquid composition comprises the following components in weight proportion: Glycerin 6g, p-Hydroxyacetophenone 0.3g, Sodium hyaluronate 0.05g, Propylene glycol 6g, Menthyl glycol 0.02g, Borneol 0.02g, Methyl diisopropyl propionamide 0.3g, Menthol 0.02g, SOLUBILISANT LRI is 0.25g, Edetate disodium 0.03g, 0.5g water-locking magnet Gentiana root extract 0.2g, Totarol 0.05g, Sodium citrate 0.0118g, Ecdoin 0.01g, Threonine 0.2g, Sodium bisulfite 0.075g, Ergothioneine 0.005g, Hydrolyzed red algae extract 0.005g, Add appropriate amount of water to 100g.

[0016] According to the use of the second aspect of the present invention, the liquid composition comprises the following components in weight proportion: Glycerin 5.4g, p-Hydroxyacetophenone 0.33g, Sodium hyaluronate 0.045g, Propylene glycol 6.6g, Menthyl glycol 0.018 g, Borneol 0.022g, Methyl diisopropyl propionamide 0.27 g, Menthol 0.022g, SOLUBILISANT LRI is 0.275g, Disodium edetate 0.027g, Water-locking magnet 0.55g, Gentiana root extract 0.18g, Totarol 0.055g, Sodium citrate 0.0106g, Ecdoin 0.011g, Threonine 0.18g, Sodium bisulfite 0.0825 g, Ergothioneine 0.0045g, Hydrolyzed red algae extract 0.0055g, Add appropriate amount of water to 100g.

[0017] According to the use of the second aspect of the present invention, the liquid composition comprises the following components in weight proportion: Glycerin 6.6g, p-Hydroxyacetophenone 0.27g, Sodium hyaluronate 0.055g, Propylene glycol 5.4g, Menthyl glycol 0.022 g, Borneol 0.018g, Methyl diisopropyl propionamide 0.33 g, Menthol 0.018g, SOLUBILISANT LRI is 0.225g, Disodium edetate 0.033g, Water-locking magnet 0.45g, Gentiana root extract 0.22g, Totarol 0.045g, Sodium citrate 0.013g, Ecdoin 0.009g, Threonine 0.22g, Sodium bisulfite 0.0675g, Ergothioneine 0.0055g, Hydrolyzed red algae extract 0.0045g, Add appropriate amount of water to 100g.

[0018] When describing the method steps in the present application, although the specific steps described therein are different from the steps described in the examples of the specific implementation methods of this paper in some details or in the language description, however, those skilled in the art can summarize the above-mentioned method steps completely according to the detailed disclosure of the full text of the application. Any embodiment of any aspect of the present application can be combined with other embodiments as long as they do not conflict. In addition, in any embodiment of any aspect of the present application, any technical feature can be applied to the technical features in other embodiments as long as they do not conflict.

[0019] The present application is further described below.

[0020] All documents cited in this application are incorporated herein by reference in their entirety, and if the meanings expressed in these documents are inconsistent with those in this application, the meanings expressed in this application shall prevail. In addition, the various terms and phrases used in this application have general meanings known to those skilled in the art, but even so, this application still hopes to provide more detailed descriptions and explanations of these terms and phrases, and if the terms and phrases mentioned are inconsistent with the known meanings, the meanings expressed in this application shall prevail.

[0021] The various raw materials mentioned above in the present invention can be easily obtained from commercial sources.

[0022] In the present invention, propylene glycol, if not used otherwise, is 1,3-propylene glycol.

[0023] In the present invention, the water-locking magnet used is Pentavitin® purchased from DSM Nutritional Products, which is a moisturizing factor for cosmetics. Water-locking magnet is a carbohydrate isomer, and its composition is very similar to the natural carbohydrate complex components in the stratum corneum, so it has good skin affinity and can be tightly bound to keratin like a magnet, so it is commonly known as "water-locking magnet". Water-locking magnet is derived from edible corn sugar (plant D-glucose), which is a carbohydrate complex with a structure similar to the carbohydrate complex (NMF natural moisturizing factor) found in the stratum corneum of human skin. It can bind to the ε-amino group of lysine in keratinocyte keratin. This unique binding mechanism makes it difficult to be washed away as a moisturizing active ingredient, and can continuously improve skin hydration until the keratinocytes naturally age and fall off.

[0024] In the present invention, the methyl diisopropyl propionamide used is purchased from Guangzhou Zhongkang Pharmaceutical Technology Co., Ltd., trade name: WS-23, and the raw material reporting code for cosmetic cooling agents is: 003301-00435-1138. Methyl diisopropyl propionamide, also known as N,2,3-trimethyl-2-isopropyl butanamide, is a high-quality cooling agent with high cooling activity without side effects such as burning, numbness and irritation. As a cooling agent, it is mainly used in candy, oral care, and medicine. N,2,3-trimethyl-2-isopropyl butanamide has a very strong cool taste and a long-lasting cooling effect. The product is mainly used as a cooling agent in medicine, oral care products, food, beverages, tobacco, cosmetics, and candy. When used in combination with flavors, it has a good compatibility synergistic effect and a significant flavoring effect. It provides a better raw material selection for new cooling products in the food, daily chemical, and pharmaceutical industries.

[0025] In the present invention, the p-hydroxyacetophenone used is purchased from Beijing Tianhong Tianda Co., Ltd., UKfinecare® HP, also known as 4-hydroxyacetophenone, which is widely used in the fields of medicine, fragrance, cosmetics, etc., and cosmetics are its main application field. P-hydroxyacetophenone has an antiseptic effect. Compared with traditional cosmetic preservatives, p-hydroxyacetophenone is non-carcinogenic and non-irritating, has stronger antibacterial and antiseptic properties, higher safety, etc., and is currently widely used in mid-to-high-end cosmetics.

[0026] In the present invention, the SOLUBILISANT LRI used is purchased from Sensient Cosmetic Technologies of France, with the cosmetic raw material reporting code: 117573-01033-4456, and the main chemical components are PPG-26-butanol polyether-26 and PEG-40 hydrogenated castor oil. SOLUBILISANT LRI is a unique surfactant mixture with a super strong solubilizing effect, which can solubilize essences, essential oils, vitamins and other oily ingredients for cosmetics into water to form a stable microemulsified system. The solubilizing ability of SOLUBILISANT LRI is particularly strong, so the amount used in the formula is much smaller than that of other similar products. It is highly safe and has been tested to be non-irritating to the skin and eyes. For more complex (mixed) hydrophobic mixtures, the solubilizing ability of SOLUBILISANT LRI is stronger, which can leave a soft and smooth feeling on the skin surface without a sticky feeling, and can show the fragrance of the essence.

[0027] In the present invention, the gentian root extract used is a cosmetic raw material purchased from Shanghai Jiayu Biotechnology Co., Ltd. under the trade name of 2.5-generation gentian anti-irritation factor®, product number: JY1004-2.5. The 2.5-generation gentian anti-irritation factor® uses authentic medicinal materials Tibetan herbal gentian and adopts original separation and extraction technology. The 2.5-generation gentian anti-irritation factor® has anti-irritation and anti-inflammatory effects and is the mainstream anti-allergic and anti-irritation raw material in the market. Adding 0.5% has a good anti-allergic and irritation-reducing effect. It is a natural plant gentian root extract that can completely replace chemical hormones for botanical anti-inflammatory, antipruritic, anti-redness and swelling.

[0028] In the present invention, the sodium hyaluronate used is easily purchased from commercial sources, and it is a sodium hyaluronate with a molecular weight of 1.2 million. Sodium hyaluronate is the sodium salt form of hyaluronic acid, also known as sodium hyaluronate, and its chemical formula is (C14H20NO11Na)n, which is a glucuronic acid, a natural polysaccharide, and is widely present in the connective tissue, skin, eyes and joint fluid of the human body. It has excellent moisturizing, anti-aging, repair and lubricating functions, and is therefore widely used in beauty, medicine and health care fields. The molecular structure of sodium hyaluronate is formed by alternating arrangement of glucuronic acid and N-acetylglucosamine, and has extremely strong water absorption capacity, and each molecule can absorb hundreds of times the water of its own weight, thereby maintaining skin hydration and improving skin elasticity. There is a significant effect. In beauty and skin care, sodium hyaluronate is commonly used in moisturizing products, such as creams, essences, facial masks, etc., to help relieve dryness, tightness and fine lines, and keep the skin smooth and moist. In addition, sodium hyaluronate is also widely used in joint treatment (such as arthritis injections), ophthalmology (such as artificial tears) and wound repair to help relieve joint pain, accelerate wound healing and relieve dry eyes. Due to its high safety and naturalness, sodium hyaluronate has become an indispensable and important ingredient in modern medicine and skin care products. Hyaluronic acid (HA) is a linear macromolecular polysaccharide composed of D-glucuronic acid and N-acetylglucosamine alternately connected by β-1,3 and β-1,4 glycosidic bonds. Its chemical structure makes it highly hydrophilic. There are a large number of hydrophilic groups such as carboxyl and hydroxyl groups on the molecular chain, which can form hydrogen bonds with water molecules, so that sodium hyaluronate has good water retention properties. Sodium hyaluronate is a biodegradable substance. In the body, it can be degraded by hyaluronidase. Hyaluronidase is an enzyme present in many tissues of the human body that can hydrolyze the glycosidic bonds of sodium hyaluronate. This degradation property gives sodium hyaluronate a great advantage in medical applications. When sodium hyaluronate is used in tissue engineering scaffolds, it can be gradually degraded as the tissue repairs and grows, making room for the formation of new tissue. Its degradation products are some small molecular sugars and other substances, which can be metabolized and absorbed by the human body and will not have adverse effects on the human body.

[0029] In the present invention, the totarol used is also known as Totarol, Luo Song phenol, CAS No. 511-15-9, purchased from Huaruibao (Guangzhou) Biotechnology Co., Ltd., with a chromatographic purity of more than 98%. Totarol has very good antibacterial and cleaning effects on human skin, body and oral cavity, and has no irritation and allergic reaction to human skin. Totarol has been widely confirmed to have efficient biological activity, human safety and product formula compatibility, and is applied to clinical medical treatment and cosmeceutical products. Totarol is a natural plant extract, a highly effective antibacterial agent, and has good antibacterial effects on Gram-positive bacteria, including streptococci, Bacillus subtilis, Staphylococcus aureus and Propionibacterium acnes. Totarol is a naturally occurring diterpene with strong antibacterial activity, has very good antibacterial and cleaning effects on human skin, body and oral cavity, and has no irritation and allergic reaction to human skin.

[0030] In the present invention, the disodium edetate, i.e., disodium edetate, is Dissolvine® NA2 purchased from Nouryon Chemicals (Ningbo) Co., Ltd., which is a commonly used excellent chelating agent. Disodium edetate is a tasteless, odorless or slightly salty white or milky white crystalline or granular powder, which is odorless and tasteless. It is soluble in water and extremely insoluble in ethanol. It is an important chelating agent that can chelate metal ions in the solution. It can prevent discoloration, deterioration, turbidity and oxidative loss of vitamin C caused by metals, and can also improve the antioxidant properties of oils and fats (trace metals in oils and fats, such as iron and copper, have the effect of promoting oil oxidation).

[0031] In the present invention, the menthol used is L-MENTHOL, which is purchased from Shanghai Gaosha Jianchen Spice Co., Ltd. Its chemical formula is C10H20O, which is a colorless needle-shaped crystal with a refreshing mint aroma. It is soluble in organic solvents such as ethanol, acetone, ether, chloroform and benzene, and slightly soluble in water. The chemical properties are relatively stable and can evaporate with steam. Menthol is biosynthesized in mint leaves and is a cyclic monoterpene as the main component of mint oil. Mint oil is a highly volatile essential oil produced by plants, and its components are mostly hemiterpenes, monoterpenes and sesquiterpenes, especially in warm climates. The yield is higher. Some important plant pigments are terpenoids or compounds containing terpenoid groups.

[0032] In the present invention, the used menthyl alcohol is purchased from Guangdong Dingchun Biopharmaceutical Technology Co., Ltd., product number: DC-1102MRC, cosmetic raw material product reporting code 004677-00414-575. Menthyl alcohol has a variety of important physiological effects in the body, and it can act on biological macromolecules such as proteins, nucleic acids and carbohydrates through various pathways, thereby regulating the physiological processes of the body. For example, menthyl alcohol has an antioxidant effect, which can remove free radicals and prevent them from damaging cells, proteins and DNA. This effect is of great significance for maintaining normal cell function, delaying aging and preventing various diseases. In addition, menthyl alcohol can also protect cells from damage such as dehydration and freeze-thaw by regulating cell osmotic pressure, and this function is of great significance for cryopreservation of cells, organisms and tissue engineering materials. Menthyl alcohol has a good moisturizing effect, can absorb moisture and retain water, and prevent dry skin. It has been widely used in cosmetics and personal care products, such as creams, milk waves and shampoos. In addition, menthyl alcohol is often used as a preservative in cosmetics to inhibit the growth of bacteria and molds and extend the shelf life of products. Due to its low toxicity and low allergenicity, menthyl glycol is relatively safe and is widely used in the cosmetics industry. Menthyl glycol is a mixture of cis- and trans-menthyl glycols obtained by hydrogenating citronellal from lemon eucalyptus leaves and catalytically condensing citronellal with water. The menthyl glycol used in the present invention is measured using the gas chromatography area normalization method, and the gas chromatography measurement conditions are: column box temperature: 80.0°C, injection temperature: 230.00°C, injection mode: split flow, flow control mode: pressure, pressure: 101.8kPa, total flow: 44.0mL / min, column flow: 2.00mL / min, linear velocity: 36.8cm / sec, purge flow: 3.0L / min, ion source temperature: 200.00°C, interface temperature: 240.00°C, solvent delay time: 4.00min. It has been determined that the total amount of cis and trans isomers of the menthyl glycol used is 98.3%. The typical chromatogram is shown in the figure. Figure 1 As shown, trans-menthenyl alcohol is at 10.4 min and cis-menthenyl alcohol is at 10.9 min.

[0033] In the present invention, the borneol used is natural borneol purchased from Jiangxi Linke Borneol Co., Ltd., which is well known as a borneol camphor leaf extract. As a natural borneol, people usually call it borneol. Natural borneol is made by extracting and processing the fresh branches and leaves of Cinnamomum camphora (L.) Presl, a plant of Lauraceae, and has the effects of invigorating the mind, clearing away heat and relieving pain. It is commonly used for fever, convulsions, stroke, phlegm, qi stagnation, coma, chest pain, red eyes, mouth sores, sore throat, pus in the ear canal, etc.

[0034] In the present invention, the sodium citrate used is purchased from Weifang Yingxuan Industrial Co., Ltd., which is also known as trisodium citrate, sodium citrate, and trisodium citrate, and is an organic acid sodium salt. The appearance is white to colorless crystals, has a cool and salty taste, and is stable in the air. The chemical formula is C6H5Na3O7, which is soluble in water and difficult to dissolve in ethanol. The aqueous solution has a slightly alkaline nature and is often used as a buffer, a chelating agent, and a bacterial culture medium. It is used in medicine for diuresis, expectorant, and anticoagulant, and is used in food, beverages, electroplating, photography, etc. It is one of the basic agents for biological experiments.

[0035] In the present invention, the ectoin used is purchased from Shantou Jiahe Co., Ltd., which is also called Ectoin, tetrahydromethylpyrimidine carboxylic acid, 2-methyl-1,4,5,6-tetrahydropyrimidine-4-carboxylic acid, and has a molecular formula of C6H10O2N2. Ectoin was discovered by Professor Galinski in the Egyptian desert in 1985. It is a natural protective component generated in the outer layer of the cell by desert halophiles under high temperature, dryness, strong UV irradiation, and high salinity environments, thereby activating the self-repair function. In addition to the desert, this fungus is also found in saline-alkali land, salt lakes, and seawater. In view of the fact that ectoin is derived from the highly halophilic bacterium Halomonas Elongata, ectoin is also called "halophilic bacteria extract". Under extreme conditions of high salt, high temperature, and high ultraviolet radiation, ectoin protects halophiles from damage. Studies have shown that ectoin also has a good repair and protective effect on the skin and is one of the bioengineering preparations used in high-end cosmetics.

[0036] In the present invention, the thioneine used is purchased from the product named SIYOMICRO-ERGO® of Shenzhen Zhongke Xinyang Co., Ltd., thioneine is also called thiothionine trimethyl inner salt, ergothioneine, 2-thio-imidazole, EGT, etc., molecular formula C9H15N3O2S, thioneine is a compound found in 1909, initially found in a fungus Claviceps purpurea, pure product is white crystal, solubility in water at room temperature 0.9mol / L, under physiological pH value and in strong alkaline solution, it will not self-oxidize.Thioneine is a natural antioxidant, which can protect cells in the human body and is an important active substance in the body. Natural antioxidants are safe and nontoxic and have become the focus of research. As a natural antioxidant, thioneine has come into people's field of vision, and it has the functions of scavenging free radicals, detoxification, maintaining the biosynthesis of DNA, the normal growth of cells and cellular immunity, etc. Ergothioneine is distributed in certain tissues and organs of mammals, mainly in red blood cells. Although no experimental studies have shown that animals can synthesize this substance, there must be ways to absorb and retain ergothioneine in animal cells. For carnivores, ergothioneine in animal tissues can meet dietary needs. Melville.DB and Eich. S found that ergothioneine also exists in cereals. Subsequent studies by Melville.DB and Genghof.DS showed that ergothioneine is a common component of many microbial cells and can be synthesized in several fungi, but not in bacteria. The precursor histidine trimethyl salt (hercynine) required for the synthesis of ergothioneine can be produced in edible fungi such as Boletus edulis, mushrooms, and Coprinus comatus; and Coprinus comatus can also produce rare amino acids such as ergothioneine.

[0037] In the present invention, the hydrolyzed red algae extract used is a cosmetic raw material purchased from CODIF INTERNATIONAL, with the trade name B-SHAPE G. Its main active ingredient is hydrolyzed red algae extract, and it also contains auxiliary glycerin and water. The cosmetic raw material reporting code is: 119371-02618-6369. B-SHAPE G is prepared by enzymatic hydrolysis of the red alga Polysiphonia brodiei, adding glycerin after clarification, and then sterilizing by filtration. It is well known that the hydrolyzed red algae extract has a strong antioxidant effect and is a scavenger of free radicals. It effectively reduces the invasion of harmful substances and maintains the health of the skin. The hydrolyzed red algae extract mainly contains alginic acid, algal protein, mannitol, linoleic acid and linolenic acid and other essential fatty acids for the human body, iodine, and 18 kinds of protein amino acids and active polypeptides that have a significant effect on the physiological process of the skin. In addition, the hydrolyzed red algae extract also contains some mineral elements necessary for the human body, such as hydrogen, phosphorus, potassium, calcium, magnesium, sulfur, iron, manganese, copper, zinc, etc.

[0038] Threonine was separated and identified from fibrin hydrolysate by WCRose in 1935. In 1936, Meger studied its spatial structure and named it threonine because of its similar structure to threose. Threonine has four isomers. L-threonine is naturally present and has physiological effects on the body. The threonine mentioned in the present invention refers to L-threonine. Threonine is an essential amino acid for the human body and is mainly used in medicine, chemical reagents, food fortifiers, feed additives, etc. Threonine is an important nutritional fortifier that can strengthen cereals, cakes, and dairy products. Like tryptophan, it has the effect of relieving human fatigue and promoting growth and development. In medicine, because threonine contains hydroxyl groups in its structure, it has a water-retaining effect on human skin, combines with oligosaccharide chains, plays an important role in protecting cell membranes, and can promote phospholipid synthesis and fatty acid oxidation in the body. Its preparation has the medicinal effect of promoting human development and resisting fatty liver. Although threonine has many excellent medical uses as mentioned above, its performance in the present invention and sodium bisulfite to give ectoine excellent stability is completely unforeseeable in the prior art.

[0039] The present invention uses the above materials to prepare a liquid composition for eye use with excellent performance, and the liquid composition for eye use can effectively relieve eye fatigue. The basic liquid composition prepared based on the method of the present invention exhibits excellent biological effects, and is typically a product approved for sale by relevant national regulatory authorities and assigned with the code Guangdong G makeup network preparation word 2023423624, and such products are used to relieve human eye fatigue through the eye and around the eye. BRIEF DESCRIPTION OF THE DRAWINGS

[0040] Figure 1 : Gas chromatogram of menthanediol.

[0041] Figure 2 : HPLC chart of solution a after heat treatment.

[0042] Figure 3 : HPLC chart of eye protection essence after heat treatment of Example 1.

[0043] Figure 4 : HPLC chart of Example 5 eye protection essence after heat treatment.

[0044] Figure 5 :The results of testing relevant items of the liquid composition of Example 7 according to the method of "Technical Standards for Safety of Cosmetics (2015 Edition)".

[0045] Figure 6 : The test results of relevant items of the liquid composition of Example 6 were tested according to relevant national standards. DETAILED DESCRIPTION

[0046] The present invention can be further described by the following examples, however, the scope of the present invention is not limited to the following examples. It will be appreciated by those skilled in the art that various changes and modifications may be made to the present invention without departing from the spirit and scope of the present invention. The present invention provides general and / or specific descriptions of the materials and test methods used in the test. Although many materials and operating methods used to achieve the purpose of the present invention are well known in the art, the present invention is still described in as much detail as possible here.

[0047] Example 1: Preparation of liquid composition for ocular use This embodiment provides a liquid composition for eye use which can be called eye protection liquid or eye protection essence liquid. The formula of the liquid composition is: Glycerin 6g, p-Hydroxyacetophenone 0.3g, Sodium hyaluronate 0.05g, Propylene glycol 6g, Menthyl glycol 0.02g, Borneol 0.02g, Methyl diisopropyl propionamide 0.3g, Menthol 0.02g, SOLUBILISANT LRI is 0.25g, Edetate disodium 0.03g, 0.5g water-locking magnet Gentiana root extract 0.2g, Totarol 0.05g, Sodium citrate 0.0118g, Ecdoin 0.01g, Ergothioneine 0.005g, Hydrolyzed red algae extract 0.005g, Add appropriate amount of water to 100g.

[0048] Preparation method: 1) Heat half of the prescribed amount of glycerol and p-hydroxyacetophenone in a water bath to completely dissolve them as pre-liquid A for later use; 2) Pre-dispersing sodium hyaluronate, 10 times its weight of water, and the remainder of glycerol to prepare pre-liquid B for later use; 3) Propylene glycol, menthyl glycol and borneol are stirred evenly, heated to 60°C-70°C to dissolve the materials, then cooled to room temperature, methyl diisopropyl propionamide and menthol are added, stirred to dissolve, and then SOLUBILISANT LRI is added and stirred evenly to prepare preformed liquid C; 4) Place an appropriate amount (about 60% of the prescribed amount) of water and disodium edetate in a liquid preparation pot, stir to dissolve, add preformed liquid B while stirring, then heat to 85°C while stirring, continue to keep warm and stir for 30 minutes, cool to 40°C, add preformed liquid A while stirring, and stir evenly; 5) Add prefabricated liquid C, water-locking magnetite, gentian root extract, totarol, sodium citrate, ectoine, ergothioneine, hydrolyzed red algae extract, and the remainder of water to the liquid obtained in the previous step in sequence, stir to dissolve at a temperature of 40° C.-45° C., filter with 0.8 μm and 0.45 μm microporous filter membranes in sequence, and package to obtain.

[0049] The pH of the obtained solution is 5.61 and the relative density is 1.036.

[0050] Ecdoin is a typical component in the liquid composition of the present invention. The inventor has found in some research experiments that the disodium edetate in the prescription has an adverse effect on the stability of Ecdoin, which can cause the loss of Ecdoin in the liquid composition. Based on this problem, the inventor has unexpectedly found that adding an appropriate amount of threonine and sodium bisulfite in the solution can avoid the above-mentioned loss of Ecdoin. A part of the experiment of this conclusion is implemented in the following way.

[0051] Solution a: Accurately weigh 10.53 mg of ectoine into a 100 ml volumetric flask, dissolve in water and make up to volume (theoretical concentration is 105.3 µg / ml, the same below). Solution b: Accurately weigh 30.25 mg of disodium edetate and 10.26 mg of ectoine into a 100 ml volumetric flask, add water to dissolve and make up to volume. Solution c: Accurately weigh 30.36 mg of disodium edetate, 10.31 mg of ectoine, and 202.14 mg of threonine into a 100 ml volumetric flask, add water to dissolve and make up to volume. Solution d: Accurately weigh 29.72 mg of disodium edetate, 10.38 mg of ectoine, and 75.14 mg of sodium bisulfite into a 100 ml volumetric flask, add water to dissolve and make up to volume. Solution e: accurately weigh 30.13 mg of disodium edetate, 10.43 mg of ectoine, 200.76 mg of threonine, and 75.38 mg of sodium bisulfite into a 100 ml volumetric flask, add water to dissolve and make up to volume; The eye protection essence of Example 1 and five solutions of solution a to solution e were sealed with ampoules and heat treated in a 70°C water bath for 24 hours. The contents of ectoine in the five solutions before and after heat treatment were determined using [HPLC method a] (which can be directly expressed by dividing the ectoine peak area by the theoretical concentration of ectoine in each solution). For each solution, the percentage obtained by dividing the content of the sample after heat treatment for 24 hours by the content of the sample without heat treatment and then multiplying by 100% was the residual rate (%) of ectoine in the solution; after measurement, the residual rate of solution a was 99.3%, the residual rate of solution b was 91.2%, the residual rate of solution c was 91.7%, the residual rate of solution d was 92.5%, the residual rate of solution e was 98.8%, and the residual rate of the eye protection essence of Example 1 was 90.8%.

[0052] In some supplementary tests, according to the ratio of 30 mg of disodium edetate, 10 mg of ectoine and 100 ml of water, the total solution obtained by adding 150 mg or 250 mg of threonine and 50 mg or 100 mg of sodium bisulfite can obtain an ectoine residual rate of more than 98.3%, indicating that adding 0.15-0.25% threonine and 0.05-0.% sodium bisulfite to a solution containing 0.03% disodium edetate and 0.01% ectoine can stabilize ectoine in an aqueous solution containing disodium edetate. Typically, the HPLC graph of solution a after heat treatment is shown in Figure 2 , HPLC chart of thermal treatment of eye protection essence in Example 1 is shown in Figure 3 .

[0053] [HPLC method a]: Agilent 1100 liquid chromatograph (equipped with UV detector), chromatographic column (Agilent ZORBAX SB-C18, 4.6×250mm, 5μm) with octadecylsilane bonded silica as filler, ZORBAX SB-C18 pre-column (4.6×10mm, 5μm); mobile phase A: weigh 4g of sodium dihydrogen phosphate and 2g of sodium octane sulfonate, dissolve in water and dilute to 1L, adjust pH to 3.0±0.1 with phosphoric acid; mobile phase B is acetonitrile; elution program: 0min mobile phase A90% / mobile phase B10%→1min mobile phase A90% / mobile phase B10%→8min mobile phase A40% / mobile phase B60%; mobile phase flow rate 1ml / min; detection wavelength 210nm; the sample to be tested is filtered with a 0.22µm microporous filter membrane, and the filtrate obtained is the test solution.

[0054] Example 2: Preparation of liquid composition for ocular use This embodiment provides a liquid composition for eye use which can be called an eye protection liquid or an eye protection essence liquid. The prescription of the liquid composition is (without disodium edetate): Glycerin 6g, p-Hydroxyacetophenone 0.3g, Sodium hyaluronate 0.05g, Propylene glycol 6g, Menthyl glycol 0.02g, Borneol 0.02g, Methyl diisopropyl propionamide 0.3g, Menthol 0.02g, SOLUBILISANT LRI is 0.25g, 0.5g water-locking magnet Gentiana root extract 0.2g, Totarol 0.05g, Sodium citrate 0.0118g, Ecdoin 0.01g, Ergothioneine 0.005g, Hydrolyzed red algae extract 0.005g, Add appropriate amount of water to 100g.

[0055] Preparation method: 1) Heat half of the prescribed amount of glycerol and p-hydroxyacetophenone in a water bath to completely dissolve them as pre-liquid A for later use; 2) Pre-dispersing sodium hyaluronate, 10 times its weight of water, and the remainder of glycerol to prepare pre-liquid B for later use; 3) Propylene glycol, menthyl glycol and borneol are stirred evenly, heated to 60°C-70°C to dissolve the materials, then cooled to room temperature, methyl diisopropyl propionamide and menthol are added, stirred to dissolve, and then SOLUBILISANT LRI is added and stirred evenly to prepare preformed liquid C; 4) Place an appropriate amount of water (about 60% of the prescription amount) in a liquid preparation pot, add preformed liquid B while stirring, then heat to 85°C while stirring, continue to keep warm and stir for 30 minutes, cool to 40°C, add preformed liquid A while stirring, and stir evenly; 5) Add prefabricated liquid C, water-locking magnetite, gentian root extract, totarol, sodium citrate, ectoine, ergothioneine, hydrolyzed red algae extract, and the remainder of water to the liquid obtained in the previous step in sequence, stir to dissolve at a temperature of 40° C.-45° C., filter with 0.8 μm and 0.45 μm microporous filter membranes in sequence, and package to obtain.

[0056] Example 3: Preparation of liquid composition for ocular use This embodiment provides a liquid composition for eye use which can be called eye protection liquid or eye protection essence liquid. The prescription of the liquid composition is (with threonine): Glycerin 6g, p-Hydroxyacetophenone 0.3g, Sodium hyaluronate 0.05g, Propylene glycol 6g, Menthyl glycol 0.02g, Borneol 0.02g, Methyl diisopropyl propionamide 0.3g, Menthol 0.02g, SOLUBILISANT LRI is 0.25g, Edetate disodium 0.03g, 0.5g water-locking magnet Gentiana root extract 0.2g, Totarol 0.05g, Sodium citrate 0.0118g, Ecdoin 0.01g, Threonine 0.2g, Ergothioneine 0.005g, Hydrolyzed red algae extract 0.005g, Add appropriate amount of water to 100g.

[0057] Preparation method: 1) Heat half of the prescribed amount of glycerol and p-hydroxyacetophenone in a water bath to completely dissolve them as pre-liquid A for later use; 2) Pre-dispersing sodium hyaluronate, 10 times its weight of water, and the remainder of glycerol to prepare pre-liquid B for later use; 3) Propylene glycol, menthyl glycol and borneol are stirred evenly, heated to 60°C-70°C to dissolve the materials, then cooled to room temperature, methyl diisopropyl propionamide and menthol are added, stirred to dissolve, and then SOLUBILISANT LRI is added and stirred evenly to prepare preformed liquid C; 4) Place an appropriate amount (about 60% of the prescribed amount) of water and disodium edetate in a liquid preparation pot, stir to dissolve, add preformed liquid B while stirring, then heat to 85°C while stirring, continue to keep warm and stir for 30 minutes, cool to 40°C, add preformed liquid A while stirring, and stir evenly; 5) Add prefabricated liquid C, water-locking magnetite, gentian root extract, totarol, sodium citrate, ectoine, threonine, ergothioneine, hydrolyzed red algae extract, and the remainder of water to the liquid obtained in the previous step in sequence, stir to dissolve at a temperature of 40° C.-45° C., filter with 0.8 μm and 0.45 μm microporous filter membranes in sequence, and package to obtain.

[0058] Example 4: Preparation of liquid composition for ocular use This embodiment provides a liquid composition for eye use which can be called eye protection liquid or eye protection essence liquid. The prescription of the liquid composition is (with sodium bisulfite): Glycerin 6g, p-Hydroxyacetophenone 0.3g, Sodium hyaluronate 0.05g, Propylene glycol 6g, Menthyl glycol 0.02g, Borneol 0.02g, Methyl diisopropyl propionamide 0.3g, Menthol 0.02g, SOLUBILISANT LRI is 0.25g, Edetate disodium 0.03g, 0.5g water-locking magnet Gentiana root extract 0.2g, Totarol 0.05g, Sodium citrate 0.0118g, Ecdoin 0.01g, Sodium bisulfite 0.075g, Ergothioneine 0.005g, Hydrolyzed red algae extract 0.005g, Add appropriate amount of water to 100g.

[0059] Preparation method: 1) Heat half of the prescribed amount of glycerol and p-hydroxyacetophenone in a water bath to completely dissolve them as pre-liquid A for later use; 2) Pre-dispersing sodium hyaluronate, 10 times its weight of water, and the remainder of glycerol to prepare pre-liquid B for later use; 3) Propylene glycol, menthyl glycol and borneol are stirred evenly, heated to 60°C-70°C to dissolve the materials, then cooled to room temperature, methyl diisopropyl propionamide and menthol are added, stirred to dissolve, and then SOLUBILISANT LRI is added and stirred evenly to prepare preformed liquid C; 4) Place an appropriate amount (about 60% of the prescribed amount) of water and disodium edetate in a liquid preparation pot, stir to dissolve, add preformed liquid B while stirring, then heat to 85°C while stirring, continue to keep warm and stir for 30 minutes, cool to 40°C, add preformed liquid A while stirring, and stir evenly; 5) Add prefabricated liquid C, water-locking magnetite, gentian root extract, totarol, sodium citrate, ectoine, sodium bisulfite, ergothioneine, hydrolyzed red algae extract, and the remainder of water to the liquid obtained in the previous step in sequence, stir to dissolve at a temperature of 40° C.-45° C., filter with 0.8 μm and 0.45 μm microporous filter membranes in sequence, and package to obtain.

[0060] Example 5: Preparation of liquid composition for ocular use This embodiment provides a liquid composition for eye use which can be called eye protection liquid or eye protection essence liquid. The prescription of the liquid composition is (with threonine and sodium bisulfite): Glycerin 6g, p-Hydroxyacetophenone 0.3g, Sodium hyaluronate 0.05g, Propylene glycol 6g, Menthyl glycol 0.02g, Borneol 0.02g, Methyl diisopropyl propionamide 0.3g, Menthol 0.02g, SOLUBILISANT LRI is 0.25g, Edetate disodium 0.03g, 0.5g water-locking magnet Gentiana root extract 0.2g, Totarol 0.05g, Sodium citrate 0.0118g, Ecdoin 0.01g, Threonine 0.2g, Sodium bisulfite 0.075g, Ergothioneine 0.005g, Hydrolyzed red algae extract 0.005g, Add appropriate amount of water to 100g.

[0061] Preparation method: 1) Heat half of the prescribed amount of glycerol and p-hydroxyacetophenone in a water bath to completely dissolve them as pre-liquid A for later use; 2) Pre-dispersing sodium hyaluronate, 10 times its weight of water, and the remainder of glycerol to prepare pre-liquid B for later use; 3) Propylene glycol, menthyl glycol and borneol are stirred evenly, heated to 60°C-70°C to dissolve the materials, then cooled to room temperature, methyl diisopropyl propionamide and menthol are added, stirred to dissolve, and then SOLUBILISANT LRI is added and stirred evenly to prepare preformed liquid C; 4) Place an appropriate amount (about 60% of the prescribed amount) of water and disodium edetate in a liquid preparation pot, stir to dissolve, add preformed liquid B while stirring, then heat to 85°C while stirring, continue to keep warm and stir for 30 minutes, cool to 40°C, add preformed liquid A while stirring, and stir evenly; 5) Add prefabricated liquid C, water-locking magnet, gentian root extract, totarol, sodium citrate, ectoine, threonine, sodium bisulfite, ergothioneine, hydrolyzed red algae extract, and the remainder of water to the liquid obtained in the previous step in sequence, stir to dissolve at a temperature of 40° C.-45° C., filter with 0.8 μm and 0.45 μm microporous filter membranes in sequence, and package to obtain.

[0062] Example 6: Preparation of liquid composition for ocular use This embodiment provides a liquid composition for eye use which can be called eye protection liquid or eye protection essence liquid. The formula of the liquid composition is: Glycerin 5.4g, p-Hydroxyacetophenone 0.33g, Sodium hyaluronate 0.045g, Propylene glycol 6.6g, Menthyl glycol 0.018 g, Borneol 0.022g, Methyl diisopropyl propionamide 0.27 g, Menthol 0.022g, SOLUBILISANT LRI is 0.275g, Disodium edetate 0.027g, Water-locking magnet 0.55g, Gentiana root extract 0.18g, Totarol 0.055g, Sodium citrate 0.0106g, Ecdoin 0.011g, Threonine 0.18g, Sodium bisulfite 0.0825 g, Ergothioneine 0.0045g, Hydrolyzed red algae extract 0.0055g, Add appropriate amount of water to 100g.

[0063] Preparation method: 1) Heat half of the prescribed amount of glycerol and p-hydroxyacetophenone in a water bath to completely dissolve them as pre-liquid A for later use; 2) Pre-dispersing sodium hyaluronate, 10 times its weight of water, and the remainder of glycerol to prepare pre-liquid B for later use; 3) Propylene glycol, menthyl glycol and borneol are stirred evenly, heated to 60°C-70°C to dissolve the materials, then cooled to room temperature, methyl diisopropyl propionamide and menthol are added, stirred to dissolve, and then SOLUBILISANT LRI is added and stirred evenly to prepare preformed liquid C; 4) Place an appropriate amount (about 60% of the prescribed amount) of water and disodium edetate in a liquid preparation pot, stir to dissolve, add preformed liquid B while stirring, then heat to 85°C while stirring, continue to keep warm and stir for 30 minutes, cool to 40°C, add preformed liquid A while stirring, and stir evenly; 5) Add prefabricated liquid C, water-locking magnet, gentian root extract, totarol, sodium citrate, ectoine, threonine, sodium bisulfite, ergothioneine, hydrolyzed red algae extract, and the remainder of water to the liquid obtained in the previous step in sequence, stir to dissolve at a temperature of 40° C.-45° C., filter with 0.8 μm and 0.45 μm microporous filter membranes in sequence, and package to obtain.

[0064] Example 7: Preparation of liquid composition for ocular use This embodiment provides a liquid composition for eye use which can be called eye protection liquid or eye protection essence liquid. The formula of the liquid composition is: Glycerin 6.6g, p-Hydroxyacetophenone 0.27g, Sodium hyaluronate 0.055g, Propylene glycol 5.4g, Menthyl glycol 0.022 g, Borneol 0.018g, Methyl diisopropyl propionamide 0.33 g, Menthol 0.018g, SOLUBILISANT LRI is 0.225g, Disodium edetate 0.033g, Water-locking magnet 0.45g, Gentiana root extract 0.22g, Totarol 0.045g, Sodium citrate 0.013g, Ecdoin 0.009g, Threonine 0.22g, Sodium bisulfite 0.0675g, Ergothioneine 0.0055g, Hydrolyzed red algae extract 0.0045g, Add appropriate amount of water to 100g.

[0065] Preparation method: 1) Heat half of the prescribed amount of glycerol and p-hydroxyacetophenone in a water bath to completely dissolve them as pre-liquid A for later use; 2) Pre-dispersing sodium hyaluronate, 10 times its weight of water, and the remainder of glycerol to prepare pre-liquid B for later use; 3) Propylene glycol, menthyl glycol and borneol are stirred evenly, heated to 60°C-70°C to dissolve the materials, then cooled to room temperature, methyl diisopropyl propionamide and menthol are added, stirred to dissolve, and then SOLUBILISANT LRI is added and stirred evenly to prepare preformed liquid C; 4) Place an appropriate amount (about 60% of the prescribed amount) of water and disodium edetate in a liquid preparation pot, stir to dissolve, add preformed liquid B while stirring, then heat to 85°C while stirring, continue to keep warm and stir for 30 minutes, cool to 40°C, add preformed liquid A while stirring, and stir evenly; 5) Add prefabricated liquid C, water-locking magnet, gentian root extract, totarol, sodium citrate, ectoine, threonine, sodium bisulfite, ergothioneine, hydrolyzed red algae extract, and the remainder of water to the liquid obtained in the previous step in sequence, stir to dissolve at a temperature of 40° C.-45° C., filter with 0.8 μm and 0.45 μm microporous filter membranes in sequence, and package to obtain.

[0066] In addition, the liquid compositions obtained in Examples 2 to 7 were treated with reference to the method of heat treatment at 70°C for 24 hours described above, and the contents of ectoine in the six solutions before and after heat treatment were determined according to [HPLC method a]. The residual rate (%) of ectoine in each solution after heat treatment for 24 hours was calculated. The results showed that the residual rate of the eye essence in Example 2 was 99.1%, the residual rate of the eye essence in Example 3 was 91.3%, the residual rate of the eye essence in Example 4 was 92.9%, the residual rate of the eye essence in Example 5 was 99.3%, the residual rate of the eye essence in Example 6 was 99.0%, and the residual rate of the eye essence in Example 7 was 99.2%. These results are basically consistent with the results obtained from solutions a to e above. Typically, the HPLC graph of the eye essence in Example 5 after heat treatment is shown in Figure 4 .

[0067] The pH values ​​of the liquid compositions obtained in Examples 2 to 7 are all within the range of 5.0 to 6.0, for example, the pH value of the liquid composition obtained in Example 5 is 5.52. The relative densities of the liquid compositions obtained in Examples 2 to 7 are all within the range of 1.01 to 1.05, for example, the relative density of the liquid composition obtained in Example 5 is 1.027.

[0068] Example 8: Quality inspection of liquid composition In this example, the seven liquid compositions obtained in Examples 1 to 7 were tested for mercury, lead, arsenic, cadmium, dioxane, and pH value (25°C) according to the method of the "Technical Specification for Safety of Cosmetics (2015 Edition)". All samples met the standard limit requirements. For example, the results of the test of the liquid composition in Example 7 commissioned by Huace Testing Company are shown in Figure 5 .

[0069] In this example, the seven liquid compositions obtained in Examples 1 to 7 were tested for mercury, lead, arsenic, cadmium, dioxane, and pH value (25°C) according to the method of the "Technical Specification for Safety of Cosmetics (2015 Edition)". All samples met the standard limit requirements. For example, the results of the test of the liquid composition in Example 7 commissioned by Huace Testing Company are shown in Figure 5 .

[0070] In this example, according to "QB / T 2660-2004 <Lotion>", "Safety Technical Specifications for Cosmetics (2015 Edition)", and "GB / T13531.4-2013 <General Test Method for Cosmetics - Determination of Relative Density>", 15 items such as cold resistance, heat resistance, appearance, fragrance, and pH of the seven liquid compositions obtained in Examples 1 to 7 were tested. All samples met the standard limit values. For example, the test results of the liquid composition in Example 6 commissioned by Huace Testing Company are shown in FIG. Figure 6 .

[0071] In addition, in this example, diethylene glycol in the seven liquid compositions obtained in Examples 1 to 7 was determined in accordance with QB / T 5411-2019 <Determination of diethylene glycol, a banned substance in cosmetics, by gas chromatography>. The national standard stipulates that the limit should be <400 mg / kg, and the actual measured results of diethylene glycol in the seven liquid compositions were all undetectable.

[0072] The present invention uses the materials in the formulas listed in Examples 1 to 7 to prepare a liquid composition for eye use with excellent performance, and the liquid composition for eye use can effectively relieve eye fatigue. The basic liquid composition prepared based on the method of the present invention exhibits excellent biological effects. A typical product is an eye protection essence product that has been approved for marketing by relevant national regulatory authorities and assigned the code Guangdong G makeup network preparation number 2023423624 and is allowed to be sold. This type of product is used for relieving human eye fatigue outside the eye and around the eye and exhibits excellent effects; for example, 38 volunteer subjects (23 females and 15 males, aged between 26 and 35 years old) who often use electronic screens and are often troubled by visual fatigue were given the eye protection essence. About 0.2 ml was applied to the outer eye (within 2 cm of the outer periphery of the upper and lower eyelids) each time during 8:00-9:00, 11:00-12:00, 14:00-15:00, and 19:00-20:00 every day and gently rubbed for 10 seconds. It was used continuously for 2 weeks, during which electronic screens were used at the usual frequency. After using the eye protection essence for 2 days, 34 subjects (21 females and 13 males) felt that their eyesight fatigue was significantly relieved.

[0073] The present invention illustrates the detailed method of the present invention through the above-mentioned embodiments, but the present invention is not limited to the above-mentioned detailed method, that is, it does not mean that the present invention must rely on the above-mentioned detailed method to be implemented. Those skilled in the art should understand that any improvement of the present invention, equivalent replacement of various raw materials of the product of the present invention, addition of auxiliary components, selection of specific methods, etc., all fall within the protection scope and disclosure scope of the present invention.

Claims

1. A liquid composition for eye use, comprising the following components in weight proportion: 5.4g-6.6g of glycerin, 0.27g-0.33g of p-hydroxyacetophenone, 0.045g-0.055g of sodium hyaluronate, 5.4g-6.6g of propylene glycol, 0.018g-0.022g of menthyl glycol, 0.018g-0.022g of borneol, 0.27g-0.33g of methyl diisopropyl propionamide, 0.018g-0.022g of menthol, 0.225g-0.275g of SOLUBILISANT LRI, 0.027g-0.033g of disodium edetate, 0.45g-0.55g of water-locking magnetite, 0.18g-0.22g of gentian root extract, and 0.045g of totarol ~0.055g, sodium citrate 0.0106g~0.013g, ectoine 0.009g ~0.011g, ergothioneine 0.0045g~0.0055g, hydrolyzed red algae extract 0.0045g ~0.0055g, water amount to 100g.

2. The liquid composition according to claim 1, which is prepared by a method comprising the steps of: 1) Heat half of the prescribed amount of glycerol and p-hydroxyacetophenone in a water bath to completely dissolve them as pre-liquid A for later use; 2) Pre-dispersing sodium hyaluronate, 10 times its weight of water, and the remainder of glycerol to prepare pre-liquid B for later use; 3) Propylene glycol, menthyl glycol and borneol are stirred evenly, heated to 60°C-70°C to dissolve the materials, then cooled to room temperature, methyl diisopropyl propionamide and menthol are added, stirred to dissolve, and then SOLUBILISANT LRI is added and stirred evenly to prepare preformed liquid C; 4) Place appropriate amount of water and disodium edetate in a liquid preparation pot, stir to dissolve, add preformed liquid B while stirring, then heat to 85°C while stirring, continue to keep warm and stir for 30 minutes, cool to 40°C, add preformed liquid A while stirring, and stir evenly; 5) Add prefabricated liquid C, water-locking magnet, gentian root extract, totarol, sodium citrate, ectoine, ergothioneine, hydrolyzed red algae extract, and the remainder of water to the liquid obtained in the previous step in sequence, stir to dissolve at a temperature of 40°C-45°C, filter with 0.8µm and 0.45µm microporous filter membranes in sequence, and pack to obtain; for example, the liquid composition also includes threonine and / or sodium bisulfite; for example, it also includes 0.18g~0.22g of threonine and / or 0.0675g~0.0825g of sodium bisulfite; for example, the threonine and / or sodium bisulfite are added together with ectoine.

3. The liquid composition according to claim 1, comprising the following components in weight proportion: 6g glycerol, 0.3g p-hydroxyacetophenone, 0.05g sodium hyaluronate, 6g propylene glycol, 0.02g menthyl glycol, 0.02g borneol, 0.3g methyl diisopropyl propionamide, 0.02g menthol, 0.25g SOLUBILISANT LRI, 0.03g disodium edetate, 0.5g water-locking magnetite, 0.2g gentian root extract, 0.05g totarol, 0.0118g sodium citrate, 0.01g ectoine, 0.2g threonine, 0.075g sodium bisulfite, 0.005g ergothioneine, 0.005g hydrolyzed red algae extract, and water (qs) to 100g.

4. The liquid composition according to claim 1, comprising the following components in weight proportion: 5.4 g glycerol, 0.33 g p-hydroxyacetophenone, 0.045 g sodium hyaluronate, 6.6 g propylene glycol, 0.018 g menthane glycol, 0.022 g borneol, 0.27 g methyl diisopropyl propionamide, 0.022 g menthol, 0.275 g SOLUBILISANT LRI, 0.027 g disodium edetate, 0.55 g water-locking magnetite, 0.18 g gentian root extract, 0.055 g totarol, 0.0106 g sodium citrate, 0.011 g ectoine, 0.18 g threonine, 0.0825 g sodium bisulfite, 0.0045 g ergothioneine, 0.0055 g hydrolyzed red algae extract, and water, q.s. to 100 g.

5. The liquid composition according to claim 1, comprising the following components in weight proportion: 6.6 g glycerol, 0.27 g p-hydroxyacetophenone, 0.055 g sodium hyaluronate, 5.4 g propylene glycol, 0.022 g menthane glycol, 0.018 g borneol, 0.33 g methyl diisopropyl propionamide, 0.018 g menthol, 0.225 g SOLUBILISANT LRI, 0.033 g disodium edetate, 0.45 g water-locking magnetite, 0.22 g gentian root extract, 0.045 g totarol, 0.013 g sodium citrate, 0.009 g ectoine, 0.22 g threonine, 0.0675 g sodium bisulfite, 0.0055 g ergothioneine, 0.0045 g hydrolyzed red algae extract, and water, q.s. to 100 g.

6. Use of a liquid composition in the preparation of a product for relieving eye fatigue, the liquid composition comprising the following components in weight proportion: 5.4g-6.6g of glycerol, 0.27g-0.33g of p-hydroxyacetophenone, 0.045g-0.055g of sodium hyaluronate, 5.4g-6.6g of propylene glycol, 0.018g-0.022g of menthyl glycol, 0.018g-0.022g of borneol, 0.27g-0.33g of methyl diisopropyl propionamide, 0.018g-0.022g of menthol, 0.225g-0.275g of SOLUBILISANT LRI, 0.027g-0.033g of disodium edetate, 0.45g-0.55g of water-locking magnetite, 0.18g-0.22g of gentian root extract, and 0.045g of totarol ~0.055g, sodium citrate 0.0106g~0.013g, ectoine 0.009g ~0.011g, ergothioneine 0.0045g~0.0055g, hydrolyzed red algae extract 0.0045g ~0.0055g, water amount to 100g.

7. The method according to claim 6, wherein the liquid composition is prepared by a method comprising the following steps: 1) Heat half of the prescribed amount of glycerol and p-hydroxyacetophenone in a water bath to completely dissolve them as pre-liquid A for later use; 2) Pre-dispersing sodium hyaluronate, 10 times its weight of water, and the remainder of glycerol to prepare pre-liquid B for later use; 3) Propylene glycol, menthyl glycol and borneol are stirred evenly, heated to 60°C-70°C to dissolve the materials, then cooled to room temperature, methyl diisopropyl propionamide and menthol are added, stirred to dissolve, and then SOLUBILISANT LRI is added and stirred evenly to prepare preformed liquid C; 4) Place an appropriate amount (about 60% of the prescribed amount) of water and disodium edetate in a liquid preparation pot, stir to dissolve, add preformed liquid B while stirring, then heat to 85°C while stirring, continue to keep warm and stir for 30 minutes, cool to 40°C, add preformed liquid A while stirring, and stir evenly; 5) Add prefabricated liquid C, water-locking magnet, gentian root extract, totarol, sodium citrate, ectoine, ergothioneine, hydrolyzed red algae extract, and the remainder of water to the liquid obtained in the previous step in sequence, stir to dissolve at a temperature of 40°C-45°C, filter with 0.8µm and 0.45µm microporous filter membranes in sequence, and pack to obtain; for example, the liquid composition also includes threonine and / or sodium bisulfite; for example, it also includes 0.18g~0.22g of threonine and / or 0.0675g~0.0825g of sodium bisulfite; for example, the threonine and / or sodium bisulfite are added together with ectoine.

8. The use according to claim 6, wherein the liquid composition comprises the following components in weight proportion: 6g glycerol, 0.3g p-hydroxyacetophenone, 0.05g sodium hyaluronate, 6g propylene glycol, 0.02g menthyl glycol, 0.02g borneol, 0.3g methyl diisopropyl propionamide, 0.02g menthol, 0.25g SOLUBILISANT LRI, 0.03g disodium edetate, 0.5g water-locking magnetite, 0.2g gentian root extract, 0.05g totarol, 0.0118g sodium citrate, 0.01g ectoine, 0.2g threonine, 0.075g sodium bisulfite, 0.005g ergothioneine, 0.005g hydrolyzed red algae extract, and water (qs) to 100g.

9. The use according to claim 6, wherein the liquid composition comprises the following components in weight proportion: 5.4g glycerol, 0.33g p-hydroxyacetophenone, 0.045g sodium hyaluronate, 6.6g propylene glycol, 0.018g menthyl glycol, 0.022g borneol, 0.27g methyl diisopropyl propionamide, 0.022g menthol, 0.275g SOLUBILISANT LRI, 0.027g disodium edetate, 0.55g water-locking magnetite, 0.18g gentian root extract, 0.055g totarol, 0.0106g sodium citrate, 0.011g ectoine, 0.18g threonine, 0.0825g sodium bisulfite, 0.0045g ergothioneine, 0.0055g hydrolyzed red algae extract, and water (qs) to 100g.

10. The use according to claim 6, wherein the liquid composition comprises the following components in weight proportion: 6.6g glycerol, 0.27g p-hydroxyacetophenone, 0.055g sodium hyaluronate, 5.4g propylene glycol, 0.022g menthyl glycol, 0.018g borneol, 0.33g methyl diisopropyl propionamide, 0.018g menthol, 0.225g SOLUBILISANT LRI, 0.033g disodium edetate, 0.45g water-locking magnetite, 0.22g gentian root extract, 0.045g totarol, 0.013g sodium citrate, 0.009g ectoine, 0.22g threonine, 0.0675g sodium bisulfite, 0.0055g ergothioneine, 0.0045g hydrolyzed red algae extract, and water (qs) to 100g.

Images